leadf
logo-loader
viewKintara Therapeutics

DelMar Pharmaceuticals' lead-product cancer treatment granted 'Fast Track' designation by US FDA

VAL-083 is a potential new treatment for recurrent glioblastoma (rGBM), a cancer of the brain and spinal cord

Cancer
‘Fast Track’ designation helps expedite the review of drugs showing promise in treating life-threatening diseases

Shares of DelMar Pharmaceuticals Inc. (NASDAQ:DMPI) surged almost 50% higher in premarket trading after the biopharmaceutical company said its lead-product cancer treatment, VAL-083,  was granted 'Fast Track' designation by the US Food and Drug Administration.

VAL-083 is a potential new treatment for recurrent glioblastoma (rGBM), a cancer of the brain and spinal cord.

‘Fast Track’ designation helps expedite the review of drugs showing promise in treating life-threatening diseases.

The firm’s interim chief executive, Saiid Zarrabian commented: "We are enthusiastic about the potential of VAL-083 to offer a meaningful clinical benefit to patients with rGBM and for the opportunity to expedite the regulatory process through the FDA's Fast Track program."

In pre-market trading, DelMar shares were 46% higher at US$1.20. 

Quick facts: Kintara Therapeutics

Price: 1.71 USD

NASDAQ:KTRA
Market: NASDAQ
Market Cap: $52.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kintara Therapeutics named herein, including the promotion by the Company of Kintara Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read